Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Galapagos  /  Galapagos januari 2018

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 26,500 25 apr 2024 16:17
  • -0,620 (-2,29%) Dagrange 26,380 - 26,980
  • 73.906 Gem. (3M) 80,8K

Galapagos januari 2018

5.109 Posts
Pagina: «« 1 ... 225 226 227 228 229 ... 256 »» | Laatste | Omlaag ↓
  1. [verwijderd] 29 januari 2018 00:25
    Dat interview is al een aantal maanden oud MrBerth.

    Wat het eerste citaat betreft:

    Voor de ontwikkeling van de pipeline is GLPG niet afhankelijk van aandelen uitgiftes.

    Maar dat wil niet perse zeggen dat er geen nieuwe aandelen uitgiftes in de planning zitten.

    Zo behoort een overname of licentiedeal door GLPG nog steeds tot de mogelijkheden. En daarvoor kan eventueel gebruik worden gemaakt van de gegeven mogelijkheid om aandelen uit te geven.
  3. [verwijderd] 29 januari 2018 00:48
    @techwhitepapers op twitter heeft op de $PRQR investors conference day Onno ontmoet.

    Hij heeft daarover getweet en een interview van een aantal maanden terug opgehaald.

    Opmerking van hem over het artikel en de jonge ontwikkelingen:

    ''in the article at the end of it, the CEO of $GLPG sees sees #CRISPR as the most interesting technology BUT made a pact w $PRQR labiotech.eu/galapagos-proqr-fibrosis... … which has the Axiomer , accomplishing the same as the #crispr however without the ethical considerations and complications''

    twitter.com/techwhitepapers/status/95...
  10. MarkvB 29 januari 2018 08:37
    SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION

    Regulated information - inside information

    Strengthens Sanofi's R&D strategy with innovative Nanobody® technology platform
    Expands growing rare blood disorders franchise with Ablynx's late-stage investigational caplacizumab aTTP treatment
    Unanimously approved by Sanofi and Ablynx Boards of Directors
    PARIS, France and GHENT, Belgium, 29 January 2018 - Sanofi [Euronext: SAN; NYSE: SNY] and Ablynx [Euronext Brussels and Nasdaq: ABLX], a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of €45 in cash, which represents an aggregate equity value of approximately €3.9 billion. The transaction was unanimously approved by both the Sanofi and Ablynx Boards of Directors.

    Sanofi's Chief Executive Officer Olivier Brandicourt commented, "With Ablynx, we continue to advance the strategic transformation of our Research and Development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders. This acquisition builds on a successful existing partnership. We are also pleased to reaffirm our commitment to Belgium, where we have invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel. We intend to maintain and support the Ablynx science center in Ghent."

    Ablynx's Chief Executive Officer Edwin Moses noted, "Since our founding in 2001, our team has been focused on unlocking the power of our Nanobody technology for patients. The results of our work are validated by clinical data. As we look ahead, we believe Sanofi's global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline. Our Board of Directors feels strongly that this transaction represents compelling value for shareholders and maximizes the potential of our pipeline to the benefit of all stakeholders."

    Sustaining Innovation in R&D

    The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules.

    Nanobodies are a novel class of proprietary next generation biologicals. Ablynx is at the leading edge of Nanobody technology supporting a deep pipeline of more than 45 proprietary and partnered candidates for a wide range of therapeutic areas such as hematology, inflammation, immuno-oncology and respiratory diseases. Eight Nanobodies have entered clinical development.

    Sanofi is committed to accelerating development and maximizing the commercial potential of Ablynx's ongoing and emerging programs.

    Strengthening Sanofi's Platform in Rare Blood Disorders

    Ablynx's most-advanced product in development is caplacizumab (anti-vWF Nanobody), a wholly-owned development program for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). The product is already filed in the European Union and expected to be filed in the U.S. during the first half of this year. Caplacizumab, if approved, would be the first-in-class treatment for this acute, life-threatening disease.
    The addition of caplacizumab to Sanofi's platform strengthens its position in rare blood disorders, complementing the recently announced agreements to acquire Bioverativ and obtain global rights for fitusiran from Alnylam.

    Combining Complementary Capabilities to Address Respiratory Syncytial Virus (RSV) Infections

    Ablynx's ALX-0171, an inhaled anti-RSV Nanobody, currently in Phase 2b, is a potential breakthrough for the symptomatic treatment of RSV infections-for which there is no widely used therapy available-and is very complementary to Sanofi Pasteur RSV associated programs.

    Delivering Long-Term Shareholder Value

    The addition of Ablynx is anticipated to drive meaningful long-term value for Sanofi's shareholders by enhancing its pipeline and research capabilities. Including R&D expenses, the acquisition is expected to be neutral to Business EPS[1] in 2018 and 2019.

    Transaction Terms

    Under the terms of the agreement, Sanofi will launch public offers to acquire all of the outstanding ordinary shares (including shares represented by ADSs), warrants and convertible bonds of Ablynx in cash. Sanofi has complied with the formalities set forth in the Belgian takeover legislation and filed the mandatory documents with the Belgian Financial Services and Markets Authority (FSMA). A notice was published by the FSMA on its website.

    The consummation of the public offers is subject to customary conditions, including the tender of securities representing at least 75% of the outstanding shares of Ablynx at the end of the initial acceptance period of the Belgian Tender Offer, and the receipt of required regulatory approvals. The public offers are expected to be launched by the beginning of the second quarter of 2018.

    In accordance with the Belgian requirement of certainty of funds, Sanofi has entered into a bank credit facility, BNP Paribas Fortis SA/NA acting as the sole credit facility arranger. Subject to the satisfaction or waiver of customary closing conditions, the transaction is expected to close by the end of the second quarter 2018.

    Morgan Stanley and Lazard are acting as financial advisors to Sanofi. J.P. Morgan is acting as financial advisor to Ablynx. Weil, Gotshal & Manges LLP and NautaDutilh are serving as legal counsels to Sanofi. Eubelius CVBA, Goodwin Procter LLP and Linklaters LLP are serving as legal counsels to Ablynx.

    Sanofi Conference Call

    Sanofi will host a webcast live on Sanofi's website at 2.30pm CET / 8.30am EST on Monday, 29 January 2018. The webcast details and full presentation will be made available on Sanofi's Investor Relations webpage.

    globenewswire.com/news-release/2018/0...
  14. Beurskingpin 29 januari 2018 08:48
    quote:

    moneymaker_BX schreef op 29 januari 2018 08:43:

    Vandaag fors up Wat een vette premie op Ablynx
    Pas die maar eens toe op Galapagos dan ga je richting 150

    Ne, toch niet. Dan ga je eerder richting 200 euro aangezien het eerste bod bij ablynx binnenkwam toen ze nog maar 22euro aan het noteren waren.
5.109 Posts
Pagina: «« 1 ... 225 226 227 228 229 ... 256 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!